Clinical Trial

A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] SHR6508.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-10; most recent amendment 2026-03-20.
Status change: Active, Not Recruiting → Completed 2026-03-20
Status change: Recruiting → Active, Not Recruiting 2025-04-16
Trial Details
NCT Number NCT06877247
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Secondary Hyperparathyroidism
Enrollment 5 participants
Start Date 2024-12-23
Primary Completion 2025-04-04 (estimated)
Study Completion 2025-10-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-23